ARCHIVES

ASCO’s Lichter Says. Dingell, Stupak Urge FDA To “Act With Due Haste To Avoid Endangering Patients” Steered To ESAs.

This article is from The Cancer Letter archive.

Vol. 34 No. 09 | March 7, 2008

Download PDF Visit The Full Archive

Related Articles

Schmidt Already Working For NIH Despite His Opposition To Kennedy’s New Research Panel

April 12, 1974

It is The First FDA Withdrawl Of An Accelerated Approval

November 18, 2011

More Bad News for AVEO As Tivozanib Partner Bids Adieu

May 31, 2013

NCI-Approved Clinical Trials

November 26, 2004

Regulatory Approvals: FDA expanded the approved use of Cyramza to include metastatic NSCLC

December 19, 2014

New Version Of NCI Proposed IP Agreement Quiets Some Unease At Cooperative Groups; Advisors Urge “No Paralysis” While Awaiting New Language

November 13, 2009